ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Yuhan and Chong Kun Dang Pharmaceutical side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

YuhanChong Kun Dang Pharmaceutical
studies on the registry174299
open to participants now3514
phase 3 studies under way52
reach primary completion within a year104
programswith a study of their own in two years5318

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseYuhanChong Kun Dang Pharmaceutical
Phase 1

Yuhan: 45 of its 53 programs at phase 1

  1. AD-1161phase 1
  2. AD-116Aphase 1
  3. AD-118phase 1
  4. AD-230phase 1
  5. PA-111phase 1

and 40 more — sign in to see them all

85%

Chong Kun Dang Pharmaceutical: 13 of its 18 programs at phase 1

  1. CKD-383phase 1
  2. CKD-215phase 1
  3. CKD-512phase 1
  4. CKD-704phase 1
  5. CKD-706phase 1

and 8 more — sign in to see them all

72%
Phase 2

Yuhan: 3 of its 53 programs at phase 2

  1. AD-211phase 2
  2. lesigerceptphase 2
  3. YH32364phase 2
6%

Chong Kun Dang Pharmaceutical: 1 of its 18 programs at phase 2

  1. Anti-c-Met/MMAE Antibody-drug Conjugate CKD-703phase 2
6%
Phase 3

Yuhan: 5 of its 53 programs at phase 3

  1. AD-227Bphase 3
  2. AD-233Aphase 3
  3. AD-233Bphase 3
  4. AD-2282phase 3
  5. YHP2401phase 3
9%

Chong Kun Dang Pharmaceutical: 2 of its 18 programs at phase 3

  1. CKD-843phase 3
  2. lobeglitazonephase 3
11%
Approved, new studies00%

Chong Kun Dang Pharmaceutical: 2 of its 18 programs at approved, new studies

  1. empagliflozinapproved, new study
  2. Everolimusapproved, new study
11%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Yuhan10 readouts · 0 phase 3

Yuhan, Nov ’26: 3 programs whose next study reaches primary completion

  1. AD-234phase 1 · Nov 0 · NCT07717775
  2. AD-2341phase 1 · Nov 0 · NCT07717775
  3. AD-2342phase 1 · Nov 0 · NCT07717775
·

Yuhan, Jan ’27: 2 programs whose next study reaches primary completion

  1. YHP2508Bphase 1 · Jan 26 · NCT07912840
  2. YHR2602phase 1 · Jan 26 · NCT07912840

Yuhan, Feb ’27: 2 programs whose next study reaches primary completion

  1. YHP2508Aphase 1 · Feb 2 · NCT07912827
  2. YHR2601phase 1 · Feb 2 · NCT07912827

Yuhan, Mar ’27: 1 program whose next study reaches primary completion

  1. AD-211phase 2 · Mar 0 · NCT07550231
··

Yuhan, Jun ’27: 2 programs whose next study reaches primary completion

  1. YH32364phase 2 · Jun 0 · NCT06975410
  2. lesigerceptphase 2 · Jun 19 · NCT07415551
····
Chong Kun Dang Pharmaceutical5 readouts · 2 phase 3····

Chong Kun Dang Pharmaceutical, Mar ’27: 1 program whose next study reaches primary completion

  1. CKD-512phase 1 · Mar 0 · NCT07215637
··

Chong Kun Dang Pharmaceutical, Jun ’27: 2 programs whose next study reaches primary completion

  1. CKD-215phase 1 · Jun 0 · NCT07532148
  2. D215phase 1 · Jun 0 · NCT07532148
·

Chong Kun Dang Pharmaceutical, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. empagliflozinapproved, new study · Aug 0 · NCT07365358

Chong Kun Dang Pharmaceutical, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. CKD-843phase 3 · Sep 30 · NCT06916793
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Yuhan

New programs 6

  • YHP2508Aphase 1 · first study · Oct 28
  • YHP2508Bphase 1 · first study · Oct 28
  • YHR2601phase 1 · first study · Oct 28
  • YHR2602phase 1 · first study · Oct 28
  • AD-233Aphase 3 · first study · Sep 7 · Diabetes Mellitus, Type 2
  • AD-233Bphase 3 · first study · Sep 7 · Diabetes Mellitus, Type 2

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Chong Kun Dang Pharmaceutical

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 5 in all. A program counts in each condition its studies name most.

ConditionYuhanChong Kun Dang Pharmaceutical
Dyslipidemiasboth · compare here

Yuhan in Dyslipidemias: 5 programs

  1. PA-111phase 1
  2. AD-117phase 1
  3. AD-117Aphase 1
  4. AD-231phase 1
  5. PA-111Aphase 1

Their studies: Yuhan’s studies of Dyslipidemias in search

Chong Kun Dang Pharmaceutical in Dyslipidemias: 2 programs

  1. D352phase 1
  2. D794phase 1

Their studies: Chong Kun Dang Pharmaceutical’s studies of Dyslipidemias in search

Diabetes Mellitus, Type 2both · compare here

Yuhan in Diabetes Mellitus, Type 2: 2 programs

  1. AD-233Aphase 3
  2. AD-233Bphase 3

Their studies: Yuhan’s studies of Diabetes Mellitus, Type 2 in search

Chong Kun Dang Pharmaceutical in Diabetes Mellitus, Type 2: 4 programs

  1. lobeglitazonephase 3
  2. CKD-383phase 1
  3. CKD-378phase 1
  4. empagliflozinapproved, new study

Their studies: Chong Kun Dang Pharmaceutical’s studies of Diabetes Mellitus, Type 2 in search

Hypertensionboth · compare here

Chong Kun Dang Pharmaceutical in Hypertension: 1 program

  1. CKD-339phase 1

Their studies: Chong Kun Dang Pharmaceutical’s studies of Hypertension in search

Prostatic Hyperplasiaboth · compare here

Yuhan in Prostatic Hyperplasia: 3 programs

  1. AD-1161phase 1
  2. AD-116Aphase 1
  3. AD-116phase 1

Their studies: Yuhan’s studies of Prostatic Hyperplasia in search

Chong Kun Dang Pharmaceutical in Prostatic Hyperplasia: 2 programs

  1. CKD-846phase 1
  2. D091phase 1

Their studies: Chong Kun Dang Pharmaceutical’s studies of Prostatic Hyperplasia in search

Heart Failureboth · compare here

Yuhan in Heart Failure: 1 program

  1. AD-118phase 1

Their studies: Yuhan’s studies of Heart Failure in search

Chong Kun Dang Pharmaceutical in Heart Failure: 1 program

  1. empagliflozinapproved, new study

Their studies: Chong Kun Dang Pharmaceutical’s studies of Heart Failure in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Yuhan 1 of 53 · Chong Kun Dang Pharmaceutical 3 of 18 programs (4 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.